!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
News|Articles|June 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 6
- Volume 4
- Issue 6
FDA Panel Recommends Approval of Roferon-A for Treatment of CML
WASHINGTON--The FDA's Biological Response Modifiers Advisory Committee unanimously recommended approval of Hoffmann-La Roche Inc.'s Roferon-A (interferon alfa-2a, recombinant) for the treatment of adult patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML). The interferon is currently approved for use in hairy cell leukemia and AIDS related Kaposi's sarcoma.
Advertisement
WASHINGTON--The FDA's Biological Response Modifiers Advisory Committeeunanimously recommended approval of Hoffmann-La Roche Inc.'s Roferon-A(interferon alfa-2a, recombinant) for the treatment of adult patientswith Philadelphia chromosome positive chronic myelogenous leukemia(CML). The interferon is currently approved for use in hairy cellleukemia and AIDS related Kaposi's sarcoma.
A large randomized study suggests that Roferon-A slows progression,elicits more cytogenetic responses, and improves survival in thesepatients. It is currently designated as an orphan drug for CML,since only 2,500 patients a year are affected with the disease.
Articles in this issue
over 31 years ago
IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphomaover 31 years ago
Dr. Peters Named Head of the Michigan Cancer Foundationover 31 years ago
Broad-Spectrum Sunscreens Block UVA and UVBover 31 years ago
Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Caover 31 years ago
Outpatient ABMT at Duke Leads to Savingsover 31 years ago
Algorithm Optimizes Value of CA125 II Screening for Ovarian Caover 31 years ago
Better Ovarian Cancer Outcome With IP Cisplatinover 31 years ago
Epirubicin Effective But Toxicity Is IncreasedAdvertisement
Related to this article
Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.
Azacitidine/venetoclax improving EFS over chemotherapy in fit patients with AML is an “important outcome,” according to Amir T. Fathi, MD.
Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
3
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5